TY - JOUR. T1 - Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital. AU - Hann, A. AU - Bohle, W. AU - Egger, Jan. AU - Zoller, W G. N1 - © Georg Thieme Verlag KG Stuttgart · New York.. PY - 2016/10. Y1 - 2016/10. N2 - Background: New chemotherapeutic strategies for locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) have been shown to improve survival in randomized clinical trials. Little is known about the use of such chemotherapies and their benefit in community-based hospitals. This retrospective study analyzes the overall survival of these patients under "real life conditions" before and after the introduction of FOLFIRINOX in 2011. Methods: We retrospectively identified consecutive patients with PDAC who were treated at our hospital from 2011 to June 2014 (2011+ cohort) and 2004 to 2010 (historical cohort). Patients were included if PDAC was diagnosed in a locally advanced or metastatic ...
TY - JOUR. T1 - A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. AU - Adjei, Alex A.. PY - 1999/9/14. Y1 - 1999/9/14. N2 - Colorectal carcinoma is an important cause of cancer morbidity and mortality. 5-fluorouracil has been the major chemotherapeutic agent for the treatment of colorectal carcinoma for the past four decades. This regimen is noncurative, and its impact on survival is unclear. Attempts at identifying more effective chemotherapeutic agents for colorectal cancer have yielded oral formulations and prodrugs of 5-fluorouracil with apparently equivalent efficacy. Specific thymidylate synthase inhibitors are now available. Platinum analogues with activity in colorectal carcinoma, and no cross-resistance to the antimetabolites have also been developed. The topoisomerase I inhibitors represent a new class of agents with a novel mechanism of action. These agents are in phase II and Phase III clinical trials, others have ...
Pembrolizumab may have a manageable toxicity profile and promising antitumor activity in recurrent or metastatic PD-L1-positive gastric cancer.
Vascularization, oxygenation, and metabolism are important parameters of a tumor, determining its development and treatment response. The overall goals of this thesis were to: 1) describe these parameters in colorectal cancer, both in animal models and in humans; 2) explore the possibility to manipulate vascularization, oxygenation and metabolism for the improvement of cytotoxic treatment; 3) monitor uptake and metabolism of fluorinated cytotoxic drugs in colorectal cancer in an early stage of the treatment. The specific questions were addressed whether vascularization as measured by dynamic contrast enhanced MRI (DCE-MRI) and uptake and metabolism of 5-fluorouracil (FU) as measured by fluorine-19 magnetic resonance spectroscopy (19F MRS) could predict response to cytotoxic treatment. This research shows that nicotinamide and carbogen can decrease tumor hypoxia in murine colon carcinoma, both in subcutaneously implanted tumors and in an orthotopic liver metastases model. Moreover, carbogen ...
The adapters IRS1 and IRS2 link growth factor receptors to downstream signaling pathways that regulate proliferation and survival. Both suppress factor-withdrawal-induced apoptosis and have been implicated in cancer progression. However, recent studi
TY - JOUR. T1 - 2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition. AU - Nepali, Kunal. AU - Kumar, Sunil. AU - Huang, Hsiang Ling. AU - Kuo, Fei Chiao. AU - Lee, Cheng Hsin. AU - Kuo, Ching Chuan. AU - Yeh, Teng Kuang. AU - Li, Yu Hsuan. AU - Chang, Jang Yang. AU - Liou, Jing Ping. AU - Lee, Hsueh Yun. PY - 2015. Y1 - 2015. N2 - This study reports the synthesis of a series of 2-aroylquinoline-5,8-diones (11-23) on the basis of scaffold hopping. The presence of a methoxy group at C6 assists the highly regioselective incorporation with various amines, and simplifies the structural identification process. Among the synthetic compounds, 6-dimethylamino-2-(3,4,5-trimethoxybenzoyl)-quinoline-5,8-dione (12) and 7-pyrrolidin-1-yl-2-(3,4,5-trimethoxybenzoyl)-quinoline-5,8-dione (23) exhibit remarkable anti-proliferative activity against the cancer cell lines tested with mean IC50 values of 0.14 and 0.27 μM, respectively. Compound 23 ...
Signal transducer and activator of transcription 3 (STAT3) plays critical roles in tumorigenesis and malignant evolution and has been intensively studied as a therapeutic target for cancer. A number of STAT3 inhibitors have been evaluated for their antitumor activity in vitro and in vivo in experimental tumor models and several approved therapeutic agents have been reported to function as STAT3 inhibitors. Nevertheless, most STAT3 inhibitors have yet to be translated to clinical evaluation for cancer treatment, presumably because of pharmacokinetic, efficacy, and safety issues. In fact, a major cause of failure of anticancer drug development is lack of efficacy. Genetic interactions among various cancer-related pathways often provide redundant input from parallel and/or cooperative pathways that drives and maintains survival environments for cancer cells, leading to low efficacy of single-target agents. Exploiting genetic interactions of STAT3 with other cancer-related pathways may provide molecular
Signal transducer and activator of transcription 3 (STAT3) plays critical roles in tumorigenesis and malignant evolution and has been intensively studied as a therapeutic target for cancer. A number of STAT3 inhibitors have been evaluated for their antitumor activity in vitro and in vivo in experimental tumor models and several approved therapeutic agents have been reported to function as STAT3 inhibitors. Nevertheless, most STAT3 inhibitors have yet to be translated to clinical evaluation for cancer treatment, presumably because of pharmacokinetic, efficacy, and safety issues. In fact, a major cause of failure of anticancer drug development is lack of efficacy. Genetic interactions among various cancer-related pathways often provide redundant input from parallel and/or cooperative pathways that drives and maintains survival environments for cancer cells, leading to low efficacy of single-target agents. Exploiting genetic interactions of STAT3 with other cancer-related pathways may provide molecular
A breakthrough international trial of a new cancer drug has given researchers renewed hope in the fight against leukaemia, with one Melbourne doctor suggesting it could end traditional chemotherapy treatments for good.
A multi-center, international, randomized, Phase III study of older untreated patients with chronic lymphocytic leukemia (CLL) demonstrated that ibrutinib, a kinase inhibitor, is significantly more effective than traditional chemotherapy with chlorambucil.
New anti-cancer drugs that are used for treating various kinds of cancer like lung cancer, breast cancer, blood cancer, myeloma, bone cancer and brain cancer have been added to IDM
A mysterious form of cell death, coded in proteins and enzymes, led to a discovery by UNC researchers uncovering a prime suspect for new cancer drug development.
BACKGROUND: TNBC is an aggressive breast cancer subtype defined by lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), and for which no approved targeted therapies have shown benefit to date. Inhibition of PARP1, a key regulator of DNA repair, has been associated with antitumor activity in both clinical and preclinical settings. Iniparib, a PARP inhibitor, has demonstrated promising efficacy and safety for treatment of patients with metastatic TNBC when combined with gemcitabine (G) and carboplatin (C), two standard chemotherapeutic agents that synergize to induce DNA damage (OShaughnessy et al. SABCS 2009). We hypothesized that by inhibiting DNA repair, iniparib potentiates antiproliferative effects and cell cycle arrest induced by G+C. METHODS: Triple-negative MDA-MB-468(-) cells were selected by fluorescence-activated cell sorting (FACS) of HER2-negative cells. Cells confirmed negative for ER, PR, and HER2 were ...
Drug resistance represents a major obstacle towards the cure of different tumor types including non‐small cell lung cancer (NSCLC), being one of the main causes of failure of antitumor therapy. Tumor cells frequently exhibit simultaneous resistance to multiple structurally unrelated drugs, a phenotype known as multidrug resistance (MDR). A major cause of the MDR phenotype is the over‐expression of members of a conserved family of transmembrane proteins (ABC transporters). Different structurally unrelated compounds, including conventional cytotoxic and target‐specific agents are substrates for ABC transporters. Cancer stem cells (CSC) refer to a subset of tumor cells with the ability to self‐renew and generate the diverse cells that comprise tumors. At present, the mechanisms contributing to the drug‐resistant phenotype of CSC are poorly understood. Some lines of evidence support that specific ABC transporters may be expressed in CSC and may be relevant therapeutic targets. The aim of ...
TY - JOUR. T1 - PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. AU - Fabian, Kellsye P.. AU - Padget, Michelle R.. AU - Donahue, Renee N.. AU - Solocinski, Kristen. AU - Robbins, Yvette. AU - Allen, Clint T.. AU - Lee, John H.. AU - Rabizadeh, Shahrooz. AU - Soon-Shiong, Patrick. AU - Schlom, Jeffrey. AU - Hodge, James W.. PY - 2020/5/20. Y1 - 2020/5/20. N2 - Background Although immune checkpoint inhibitors have revolutionized cancer treatment, clinical benefit with this class of agents has been limited to a subset of patients. Hence, more effective means to target tumor cells that express immune checkpoint molecules should be developed. For the first time, we report a novel natural killer (NK) cell line, programmed death-ligand 1 (PD-L1) targeting high-affinity natural killer (t-haNK), which was derived from NK-92 and was engineered to express high-affinity CD16, endoplasmic reticulum-retained interleukin (IL)-2, and a ...
... This report provides an overview of the Gastric and Esophageal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under
Anticancer drugs are also called anti-neoplastic agents or chemotherapeutic agents. They act upon rapidly dividing cancer cells and destroy them.
Anticancer drugs are also called anti-neoplastic agents or chemotherapeutic agents. They act upon rapidly dividing cancer cells and destroy them.
Alkaloids: -These agents block microtubular precipitation which is necessary for mitosis, i.e. they bind with the tubulin thus interfere with the assembly of spindle proteins during mitosis. (interfere with mitotic spindle formation). These include:  Vincristine (Oncovin).  Vinplastine (Velban).  Taxol  Taxotere  Eptoside Hormones: -Corticosteroids  in lymphocytic leukemia. -Androgens  in breast cancer. -Estrogens  in prostatic carcinoma. -Progestins  in endometrium carcinoma. Antibiotics: -They inhibit DNA synthesis & are used in treatment of colon, stomach, pancreas, breast & bladder cancer. -These are cytotoxic drugs.  Actinomycin D  (D-actinomycin).  Mithramycin  Mithracin.  Mitomycin  Mutamycin.  Doxo-rubicin Miscellaneous Group: -Procarbazine (Natulane): used in treating Hodgkins disease (lymph node enlargement). It is possibly an alkylating agent. -Nitrosoureas: in GIT malignancies. -L- asparaginase (Elspar): it hydrolysis L-asparagin, thus
... CHARLOTTESVILLE Va. Nov. 7 2013 /PRNewswi...(Logo: a href http://photos.prnewswire.com/prnh/20120416/PH86899LOGO...Anticancer drugs continue to suffer the highest rate of failure in cli...HemoShears contract with the National Cancer Institute will support t...,HemoShear,to,Develop,Human,Cancer,Models,to,Improve,Industry,Success,Rates,in,New,Anticancer,Drug,Development,biological,advanced biology technology,biology laboratory technology,biology device technology,latest biology technology
Antineoplastics, PI3K Delta InhibitorsThis drug class inhibits one or more of the phosphoinositide 3-kinase enzymes, which are part of the PI3K/AKT/mTOR pathway, an important signalling pathway for ma... more
DESCRIPTION (provided by applicant): This Phase II SBIR project is aimed at developing a novel type of drugs, termed SNX9-class compounds, with a unique combination of two anticancer activities. The first is a selective antiproliferative effect on tumor cells relative to normal cells. The second is the inhibition of chemotherapy- or radiation-induced expression of multiple genes encoding secreted tumor-supporting factors with mitogenic, antiapoptotic and angiogenic activities; as a result, SNX9-class compounds potentiate the induction of apoptosis by conventional chemotherapeutic drugs. Studies conducted during Phase I of this project showed that both activities of SNX9- class compounds are due to their ability to inhibit CDK3. This understudied member of the cyclin-dependent kinase (CDK) family is apparently unneeded by normal cells, based on its very low expression in normal human tissues and spontaneous germline inactivation in laboratory mice. However, CDK3 is overexpressed in different ...
Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
The long-term objective of this research program is to discover and develop new and effective chemotherapeutic agents for fight against cancer, including cytoto...
Therapy for advanced lung cancer has improved only moderately in the last 20 years. Despite the most aggressive approaches of single-agent and combination chemotherapy with these cytotoxic agents, response rates have improved only modestly, ∼20-25%, and median survival remains at 8-10 months (11, 12, 13) . Clearly, there is a need for development of novel and rationally designed therapeutic agents that can be used either as single agents or in combination with conventional cytotoxic drug regimens.. Angiogenesis inhibitors represent a very exciting approach for NSCLC patients. There is a wealth of data in the literature now documenting the requirement for angiogenesis in human tumor growth and metastasis. The inhibition of angiogenesis has proved to be an important concept and a potentially effective strategy for treatment of existing tumors and prevention of metastasis both in animals and humans. In addition to eliminating the tumors "supply line," other theoretical advantages of targeting ...
Molecular targeting in the treatment of cancer is based on the premise that the molecular basis of cancer is associated with one or more genetic abnormalities that give rise to increased production or activation of some molecules and/or decreased production or activation of others ( 2). Determination of the structure of the target enzyme allows for the design of often exquisitely selective and effective inhibitors, enabling the selective inhibition of the up-regulated group of enzymes or activation of the down-regulated. This is expected to lead to inhibition of the pathways that typify cancer and to the death of the cancer cells, with low effect on normal cells and, therefore, low toxicity. However, there are a number of problems with this strategy.. Progression of a normal cell to cancer cell has recently been shown to involve dozens of genetic mutations, and therefore, targeting even a few gene products may be ineffective ( 5- 7). Inhibition of pathways that are the hallmark of cancer may be ...
Compare hormones/antineoplastics (hormonal oncology). View important safety information, ratings, user reviews, popularity and more...
This course introduces second-year graduate students to chemotherapy agents used to combat bacterial and viral infections as well as cancers. The course develops a detailed understanding of the strategies involved in identifying drug targets in these two diverse therapeutic settings. The antibacterial lectures emphasize the problem of drug resistance and the need to develop new agents to combat resistant organisms. The anti-cancer lectures begin with a comprehensive analysis of the molecular basis of cellulartransformation leading to neoplastic disease. Lectures on cancer therapy emphasize the contrast between conventional cytotoxic chemotherapy and novel therapeutic approaches guided by recent developments in cancer research. Novel computational biology and structural biology approaches are featured throughout the course. Each student is expected to make two formal journal-club style presentations during the course and to actively participate in group discussion.. 0-3 credits, Letter graded (A, ...
Historic data suggest that GISTs do not respond to conventional cytotoxic chemotherapy, but systematic unbiased screening has not been performed. A recent large-scaled chemotherapy susceptibility screening with GIST cells showed that among a total of 89 chemotherapies, 37 have anti-cancer effect in at least one type of GIST cells. It was suggested that of these agents, transcriptional inhibitors and chemotherapies such as topoisomerase II, paclitaxel, and bortezomib would be effective ...
Determining the optimal time-window for prodrug injection is therefore of utmost importance for success of these strategies, Zaver M. Bhujwalla, lead author Cong Li and their colleagues note in a report scheduled for the Nov. 29 issue of the weekly Journal of the American Chemical Society. If the prodrug were injected before all the enzyme cleared from normal tissue, it could damage normal tissue and cause body-wide side effects, they say ...
The study findings suggest the genetic variations could eventually help researchers design more effective chemotherapeutic agents for pediatric ALL.
The anti-cancer drug is also known as an anti-neoplastic drug, it is used to treat malignancy or cancerous growths. This drug therapy may be used alone or in association with other treatments like surgery or radiant therapy.
Information within this site is not intended to replace legal, medical, or any other professional service. The information provided is not a replacement for professional advice or care. If you require nutritional, medical, or other expert services, please seek appropriate professional care. The author, contributors, publisher and their employees are not liable or held accountable for any damages arising from or in association with the application of any information contained in this Detoxification Program. Statements about the product efficacy have not been evaluated by the U.S. Food & Drug Administration nor have the products been evaluated to diagnose, treat, cure, or prevent any disease ...
To get a better understanding of this phenomenon and develop treatments to address it, Mitsiades and his colleagues developed a technique in which tumor and normal cells are "co-cultured" - that is, grown together - and exposed to hundreds or thousands of compounds in large-scale screening tests. In the technique, dubbed "cell-specific in vitro bioluminescence imaging," or CS-BLI, the cancer cells in each sample are equipped with a gene that makes them glow - a process unaffected by the normal cells nearby. By measuring the amount of light emitted by each sample after treatment, investigators can determine which compounds are most proficient at killing tumor cells, and whether this effectiveness changes when normal cells are around the tumor. (To make sure the candidate drugs arent also killing normal cells, researchers can do a "counter-screen," in which they measure the effect of each compound on the normal cells.) While there are other techniques for screening drug activity in co-cultures of ...
PubMedID: 23054141 | Geographic location of antineoplastic agent clinical trials conducted in developed and developing countries. | International journal of clinical pharmacy | 2/1/2013
Japan has become the first country to approve a new cancer pill that treats disease by interfering with DNA replication in tumour cells.
The worlds largest cancer meeting of scientists, physicians and industry has just ended in Chicago. The annual meeting of the American Society of Clinical
Technology Networks is an internationally recognised publisher that provides access to the latest scientific news, products, research, videos and posters.
There are five different strategies of combination therapies that can and are being used with cancer vaccines. All have been validated in preclinical models and several have provided preliminary evidence of clinical benefit. As the field matures, progress in this area will undoubtedly be accelerated.. (a) Conventional combination therapy. In many cases of combination therapies using two or more chemotherapeutic agents or a chemotherapeutic agent and a targeted therapy (e.g., Herceptin and docetaxel), each agent works individually with the goal of additive antitumor effects. This too has been shown in numerous preclinical models using vaccines in combination with chemotherapeutic agents. Both preclinical and early clinical studies have highlighted the following important phenomena: although vaccines are less effective in patients heavily pretreated with chemotherapy before vaccine, no detrimental effects in immune responses to vaccines have been seen in patients when vaccine is given in ...
Just a month shy of its first birthday, Blend Therapeutics of Watertown, MA, says it has secured $16 million in Series B financing. It plans to use the mon
Gemzar: Gemcitabine belongs to the group of cancer-fighting medications known as antineoplastics, and specifically to the group of antineoplastics known as antimetabolites. Gemcitabine fights cancer by preventing the growth of cancer cells, which eventually results in their destruction. It is used to treat certain types of lung cancer, bladder cancer, breast cancer, and cancer of the pancreas.
Teva-Capecitabine: Capecitabine belongs to the group of cancer-fighting medications known as antineoplastics, and specifically to the group of antineoplastics known as antimetabolites. Capecitabine fights cancer by killing cancer cells and preventing their growth. Capecitabine may be used alone or in combination with other medications to treat certain types of breast cancer and colorectal cancer.
The journal publishes pre-clinical and clinical studies on the development of new anti-cancer agents. Clinical studies of new reported anti-cancer...
The journal publishes pre-clinical and clinical studies on the development of new anti-cancer agents. Clinical studies of new reported anti-cancer...
A wide variety of research has shown that γ-tubulin activates during cell division and that it is overexpressed in a portion of cancer cells, so it holds potential as a target protein for new anticancer agents with few side effects. Despite this research, no specific inhibitors have thus far been discovered.
BNC105 is a vascular disruption agent that selectively disrupts tumor blood vessels resulting in hypoxia and necrosis. Evofosfamide (previously known as TH-302, Evo) is a nitroimidazole-triggered prodrug of bromo-isophosphoramide mustard (Br-IPM), an alkylating agent with DNA cross-linking ability. Evo is reduced by intracellular reductases, and under hypoxic conditions selectively releases Br-IPM. Evo has little activity under normoxic conditions, but is highly cytotoxic under hypoxic conditions. Both BNC105 and Evo are currently being evaluated in Phase 1-3 clinical trials. Our studies sought to establish the potential therapeutic combination of BNC105 and Evo. It was reasoned that tumor hypoxia caused by BNC105 will result in increased intratumoral activation of Evo. A greater localized conversion of Evo to Br-IPM would increase the tumor kill achieved. A dose range-finding study was conducted to define the dose level and administration schedule for the BNC105 + Evo combination. The study ...
Synonyms for cytotoxic drug in Free Thesaurus. Antonyms for cytotoxic drug. 7 words related to cytotoxic drug: antineoplastic, antineoplastic drug, cancer drug, medicament, medication, medicinal drug, medicine. What are synonyms for cytotoxic drug?
Antineoplastic agentsThese agents inhibit cell growth and proliferation. They are used for chemotherapy.Gemcitabine (Gemzar)A frequently quoted trial showed a small, but statistically significant, imp... more
Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis.
Pinpointing which colon cancer patients need chemotherapy in addition to surgery can be difficult. Studies have suggested that those with stage-2 disease arent likely to benefit from chemotherapy, so doctors may chose to bypass the treatment and its toxic side effects. Now cancer biologist Michael Clarke, MD, working with former postdoctoral scholars Piero Dalerba, MD, and Debashis Sahoo, PhD, have found …Read More. ...